Pharmaceutical Drugs Industry: Global Competitive Landscape 2021
Report Scope:
This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021. Major players, competitive intelligence, innovative technologies and company profiles are discussed in detail. The report also examines recent developments and product portfolios of major players, and it features market share analysis and rankings in the market. It includes a regulatory landscape analysis that focuses on recent regulations in regions such as the U.S., Europe and Japan.
Report Includes:
This research report incorporates an in-depth analysis of the pharmaceutical drugs market and its competitive landscape through 2021. Major players, competitive intelligence, innovative technologies and company profiles are discussed in detail. The report also examines recent developments and product portfolios of major players, and it features market share analysis and rankings in the market. It includes a regulatory landscape analysis that focuses on recent regulations in regions such as the U.S., Europe and Japan.
Report Includes:
- 71 data tables and 54 additional tables
- A brief general overview of the global pharmaceutical drugs industry competitive landscape
- Analyses of the global market trends, with historic market revenue for 2016 to 2021, estimates for 2022, market forecasts for 2022-2026, and projections of compound annual growth rates (CAGRs) through 2027
- Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on recent developments in the pharmaceutical industry
- Highlights of the current and future market potential of pharmaceutical industry along with a detailed analysis of the competitive environment, regulatory scenario and clinical trails
- Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on recent developments and region-specific macroeconomic factors on global pharmaceutical drugs marketplace
- Market assessment of the COVID-19 impact on the global pharmaceutical drugs market, along with its implications on demand and supply, price impact and various government strategic decisions
- Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
- Descriptive company profiles of the leading pharma manufacturers, including Abbott, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Pfizer Inc., Sanofi Corp., Takeda Pharmaceutical Co. Ltd. and Zydus Cadila
CHAPTER 1 INTRODUCTION
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of Report
1.4 Methodology
1.4.1 Primary Data and Information Gathering
1.4.2 Secondary Data and Information Gathering
1.5 Market Revenue Forecasts
1.6 Analyst's Credentials
1.7 BCC Custom Research
1.8 Related BCC Research Reports
CHAPTER 2 MARKET AND TECHNOLOGY BACKGROUND
2.1 Background and Definitions: Pharmaceutical Drugs
2.2 Uses of Various Drugs
2.3 Background: Innovation in the Pharmaceutical Industry
2.4 Stakeholders Involved in the Innovation Process
2.5 The Pharmaceutical Industry
2.6 The Cost of Pharmaceutical Drug Innovation
2.7 Current Trends in the Pharmaceuticals Industry
2.7.1 Digital Transformation and Technological Developments
2.7.2 Increasing R&D Spend and Shift Toward Modern Therapeutics and Technologies
2.7.3 Collaborations for Advanced Therapeutics
2.7.4 Market Consolidation for Strategic Growth and to Retain Market Leadership
2.8 Notable Trends
2.8.1 Income Growth in Developing Markets
2.8.2 Changing Structure of the Pharma and Healthcare Industry
2.8.3 Lifestyle Medicine
2.8.4 Patient-Centric Programs
2.8.5 Prevalence of Self-Care
2.8.6 Burden on Public Health System
2.9 Importance of Innovation
2.10 Challenges Facing the Sector
2.10.1 Public Health Systems
2.10.2 Balancing Patient Needs and Financial Sustainability
2.10.3 Competitiveness and Innovation
2.11 Market Dynamics
2.11.1 Drivers
2.11.2 Restraints
2.12 Opportunities
2.13 Strategies
2.14 Distribution Network
2.14.1 Asia-Pacific
2.14.2 U.S.
2.14.3 Europe
2.14.4 India
2.14.5 China
2.14.6 Japan
2.14.7 South Korea
2.15 Recommendations
CHAPTER 3 IMPACT OF COVID-19 ON THE PHARMACEUTICAL DRUG MARKET
3.1 Overview
3.2 COVID-19 Crisis
3.3 Impact on Market
3.4 Current Outlook
3.4.1 Implications on Cancer Diagnosis
3.4.2 Implications on Cancer Treatment
3.4.3 Impact on Oncology Pharmaceuticals Market
3.5 Implications on Cancer Treatment
3.5.1 Key Impacts of COVID-19
CHAPTER 4 REGULATORY STRUCTURE: PHARMACEUTICAL DRUG MARKET
4.1 Regulatory Background
4.2 Regulatory Systems for Biopharmaceuticals by Region
4.2.1 U.S.
4.2.2 Europe
4.2.3 Japan
4.3 Regulatory Systems for Pharmaceuticals by Region
4.3.1 U.S.
4.3.2 Japan
4.3.3 India
4.3.4 Brazil
4.4 Regulations for Vaccines
4.4.1 Current Regulatory Issues for Vaccines
4.4.2 Moderna Vaccine Regulation in the U.K.
4.5 Key Regulatory Updates, 2020
4.5.1 Pharmaceuticals
4.5.2 Medical Devices
4.6 Code of Federal Regulations (CFR)
4.7 Good Manufacturing Compliance (GMP) Compliance
4.8 Establishment Registration
4.9 Drug Registration and Listing
4.10 Local Agent Requirements
4.10.1 Responsibilities of the U.S. Agent
CHAPTER 5 PRICING AND REIMBURSEMENT: PHARMACEUTICALS AND BIOLOGICS
5.1 Pricing and Reimbursement Background
5.2 Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
5.2.1 U.S.
5.2.2 Europe
5.2.3 Japan
5.3 Pricing and Reimbursement Challenges for Pharmaceuticals
5.3.1 Patented Medicines Price
5.3.2 Prices of Older Drugs
5.4 Pricing and Reimbursement for Medical Devices by Region
5.4.1 U.S.
5.4.2 Europe
5.4.3 Japan
5.5 Other Parts of Asia-Pacific
CHAPTER 6 PHARMACEUTICAL DRUGS INDUSTRY: COMPETITIVE LANDSCAPE
6.1 Overview
6.2 Key Strategies of Major Pharmaceutical Drugs Manufacturers
6.2.1 Distribution Network
6.2.2 Trends
6.2.3 Mergers and Acquisitions
6.2.4 Recommendations
6.3 Key Developments of the Major Pharmaceutical Drugs Manufacturers
6.3.1 Mergers and Acquisitions in Pharmaceutical Drugs Market
6.3.2 Agreements, Joint Ventures, Expansions, Divestments and Investments, Pharmaceuticals Market
6.3.4 New Product Launches and Approvals
6.4 Long-Term Outlook
CHAPTER 7 COMPANY PROFILES
ABBOTT
ABBVIE INC.
ALEXION PHARMACEUTICALS INC.
AMGEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
ASAHI KASEI CORP.
AUROBINDO PHARMA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL MYERS SQUIBB COMPANY
CHUGAI PHARMACEUTICAL CO. LTD.
CSL LTD.
DAIICHI SANKYO CO. LTD.
DR. REDDY’S LABORATORIES LTD.
EISAI CO. LTD.
ELI LILLY AND CO.
ENDO INTERNATIONAL PLC
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
H. LUNDBECK A/S
INCYTE
IPSEN PHARMA
JOHNSON & JOHNSON SERVICES INC.
MALLINCKRODT PLC
A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.
MERCK & CO. INC.
MERCK KGAA
MODERNA INC.
NOVARTIS AG
NOVO NORDISK A/S
OTSUKA HOLDINGS CO. LTD.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
F. HOFFMANN-LA ROCHE LTD. (ROCHE)
SANOFI
SERVIER LABORATORIES
SHANGHAI PHARMACEUTICALS HOLDING
SHIONOGI & CO. LTD.
CHINA NATIONAL PHARMACEUTICAL GROUP CORP. (SINOPHARM)
STADA ARZNEIMITTEL AG
SUMITOMO PHARMA CO. LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.
VERTEX PHARMACEUTICALS INC.
VIATRIS INC.
ZYDUS CADILA
1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of Report
1.4 Methodology
1.4.1 Primary Data and Information Gathering
1.4.2 Secondary Data and Information Gathering
1.5 Market Revenue Forecasts
1.6 Analyst's Credentials
1.7 BCC Custom Research
1.8 Related BCC Research Reports
CHAPTER 2 MARKET AND TECHNOLOGY BACKGROUND
2.1 Background and Definitions: Pharmaceutical Drugs
2.2 Uses of Various Drugs
2.3 Background: Innovation in the Pharmaceutical Industry
2.4 Stakeholders Involved in the Innovation Process
2.5 The Pharmaceutical Industry
2.6 The Cost of Pharmaceutical Drug Innovation
2.7 Current Trends in the Pharmaceuticals Industry
2.7.1 Digital Transformation and Technological Developments
2.7.2 Increasing R&D Spend and Shift Toward Modern Therapeutics and Technologies
2.7.3 Collaborations for Advanced Therapeutics
2.7.4 Market Consolidation for Strategic Growth and to Retain Market Leadership
2.8 Notable Trends
2.8.1 Income Growth in Developing Markets
2.8.2 Changing Structure of the Pharma and Healthcare Industry
2.8.3 Lifestyle Medicine
2.8.4 Patient-Centric Programs
2.8.5 Prevalence of Self-Care
2.8.6 Burden on Public Health System
2.9 Importance of Innovation
2.10 Challenges Facing the Sector
2.10.1 Public Health Systems
2.10.2 Balancing Patient Needs and Financial Sustainability
2.10.3 Competitiveness and Innovation
2.11 Market Dynamics
2.11.1 Drivers
2.11.2 Restraints
2.12 Opportunities
2.13 Strategies
2.14 Distribution Network
2.14.1 Asia-Pacific
2.14.2 U.S.
2.14.3 Europe
2.14.4 India
2.14.5 China
2.14.6 Japan
2.14.7 South Korea
2.15 Recommendations
CHAPTER 3 IMPACT OF COVID-19 ON THE PHARMACEUTICAL DRUG MARKET
3.1 Overview
3.2 COVID-19 Crisis
3.3 Impact on Market
3.4 Current Outlook
3.4.1 Implications on Cancer Diagnosis
3.4.2 Implications on Cancer Treatment
3.4.3 Impact on Oncology Pharmaceuticals Market
3.5 Implications on Cancer Treatment
3.5.1 Key Impacts of COVID-19
CHAPTER 4 REGULATORY STRUCTURE: PHARMACEUTICAL DRUG MARKET
4.1 Regulatory Background
4.2 Regulatory Systems for Biopharmaceuticals by Region
4.2.1 U.S.
4.2.2 Europe
4.2.3 Japan
4.3 Regulatory Systems for Pharmaceuticals by Region
4.3.1 U.S.
4.3.2 Japan
4.3.3 India
4.3.4 Brazil
4.4 Regulations for Vaccines
4.4.1 Current Regulatory Issues for Vaccines
4.4.2 Moderna Vaccine Regulation in the U.K.
4.5 Key Regulatory Updates, 2020
4.5.1 Pharmaceuticals
4.5.2 Medical Devices
4.6 Code of Federal Regulations (CFR)
4.7 Good Manufacturing Compliance (GMP) Compliance
4.8 Establishment Registration
4.9 Drug Registration and Listing
4.10 Local Agent Requirements
4.10.1 Responsibilities of the U.S. Agent
CHAPTER 5 PRICING AND REIMBURSEMENT: PHARMACEUTICALS AND BIOLOGICS
5.1 Pricing and Reimbursement Background
5.2 Pricing and Reimbursement of Pharmaceuticals and Biologics by Region
5.2.1 U.S.
5.2.2 Europe
5.2.3 Japan
5.3 Pricing and Reimbursement Challenges for Pharmaceuticals
5.3.1 Patented Medicines Price
5.3.2 Prices of Older Drugs
5.4 Pricing and Reimbursement for Medical Devices by Region
5.4.1 U.S.
5.4.2 Europe
5.4.3 Japan
5.5 Other Parts of Asia-Pacific
CHAPTER 6 PHARMACEUTICAL DRUGS INDUSTRY: COMPETITIVE LANDSCAPE
6.1 Overview
6.2 Key Strategies of Major Pharmaceutical Drugs Manufacturers
6.2.1 Distribution Network
6.2.2 Trends
6.2.3 Mergers and Acquisitions
6.2.4 Recommendations
6.3 Key Developments of the Major Pharmaceutical Drugs Manufacturers
6.3.1 Mergers and Acquisitions in Pharmaceutical Drugs Market
6.3.2 Agreements, Joint Ventures, Expansions, Divestments and Investments, Pharmaceuticals Market
6.3.4 New Product Launches and Approvals
6.4 Long-Term Outlook
CHAPTER 7 COMPANY PROFILES
ABBOTT
ABBVIE INC.
ALEXION PHARMACEUTICALS INC.
AMGEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
ASAHI KASEI CORP.
AUROBINDO PHARMA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL MYERS SQUIBB COMPANY
CHUGAI PHARMACEUTICAL CO. LTD.
CSL LTD.
DAIICHI SANKYO CO. LTD.
DR. REDDY’S LABORATORIES LTD.
EISAI CO. LTD.
ELI LILLY AND CO.
ENDO INTERNATIONAL PLC
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
H. LUNDBECK A/S
INCYTE
IPSEN PHARMA
JOHNSON & JOHNSON SERVICES INC.
MALLINCKRODT PLC
A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.
MERCK & CO. INC.
MERCK KGAA
MODERNA INC.
NOVARTIS AG
NOVO NORDISK A/S
OTSUKA HOLDINGS CO. LTD.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
F. HOFFMANN-LA ROCHE LTD. (ROCHE)
SANOFI
SERVIER LABORATORIES
SHANGHAI PHARMACEUTICALS HOLDING
SHIONOGI & CO. LTD.
CHINA NATIONAL PHARMACEUTICAL GROUP CORP. (SINOPHARM)
STADA ARZNEIMITTEL AG
SUMITOMO PHARMA CO. LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.
VERTEX PHARMACEUTICALS INC.
VIATRIS INC.
ZYDUS CADILA
LIST OF TABLES
Table 1: Top 20 Pharmaceutical Companies, R&D Expenditures, 2021
Table 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Table 3: Countries/Region that Authorized Moderna’s Vaccine for COVID-19
Table 4: Standard Vaccine Pricing Process in the U.S.
Table 5: COVID-19 Vaccine Price Range in the U.S., by Federal Government Purchase
Table 6: Global Pharmaceutical Drug Manufacturers Market Share, 2021
Table 7: Global Pharmaceutical Drug Manufacturers Key Financials 2021
Table 8: Global Pharmaceutical Drug Manufacturers R&D Expenditure and % of R&D in Revenue, by Company, 2021
Table 9: Top 50 Best-Selling Pharmaceuticals, 2021
Table 10: Global Market for Pharmaceutical Drugs, 2016-2020
Table 11: Global Market for Pharmaceutical Drugs, Through 2027
Table 12: Global Market for Pharmaceutical Drugs, by Region, 2016-2020
Table 13: Global Market for Pharmaceutical Drugs, by Region, Through 2027
Table 14: Certification, Reorganization, R&D Facilities and Services and Solutions in the Pharmaceuticals Market
Table 15: Abbott: Financials, 2016-2021
Table 16: Abbott: Product Portfolio, by Business Segment 2021
Table 17: Abbott: Recent Developments, 2015-2020
Table 18: AbbVie: Oncology Pharmaceutical Product Portfolio
Table 19: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 20: AbbVie Inc.: Marketed Products
Table 21: AbbVie Inc.: Business Segment
Table 22: AbbVie Inc.: Financial Performance, 2018-2021
Table 23: AbbVie Inc.: Key Developments
Table 24: Alexion: Financial Performance, 2020
Table 25: Alexion: Key Developments
Table 26: Amgen: Financial Performance, 2018-2021
Table 27: Amgen: Financials, 2014-2021
Table 28: Amgen: Oncology Pharmaceuticals Product Portfolio
Table 29: Amgen: Oncology Pharmaceuticals Revenue, 2018-2020
Table 30: Amgen: Key Developments
Table 31: Astellas: Key Financials 2021
Table 32: Astellas: Oncology Pharmaceuticals Product Portfolio
Table 33: Astellas: Oncology Pharmaceuticals Revenue, 2018-2020
Table 34: Astellas: Key Developments
Table 35: AstraZeneca: Financial Performance, 2018-2021
Table 36: AstraZeneca: Oncology Pharmaceuticals Product Portfolio
Table 37: AstraZeneca: Oncology Pharmaceuticals Revenue, 2018-2020
Table 38: Aurobindo Pharma: Financial Performance, 2021
Table 39: Bausch Health Companies Inc.: Product Portfolio of Dermatology Devices
Table 40: Bayer AG: Marketed Products
Table 41: Bayer AG: Oncology Pharmaceuticals Product Portfolio
Table 42: Bayer AG: Oncology Pharmaceuticals Revenue, 2018-2020
Table 43: Bayer AG: Key Financials, 2021
Table 44: Biogen: Key Financials, 2021
Table 45: Bristol-Myers Squibb: Financial Performance, 2018-2021
Table 46: Bristol-Myers Squibb: Oncology Pharmaceuticals Product Portfolio
Table 47: Bristol-Myers Squibb: Oncology Pharmaceuticals Revenue, 2018-2020
Table 48: CSL Ltd. (Seqirus): Vaccines Offered
Table 49: CSL Ltd. (Seqirus): Recent Developments
Table 50: Daiichi Sankyo Co. Ltd.: Net Revenue 2021
Table 51: Dr. Reddy’s: Key Financials 2021
Table 52: Eisai: Key Financials, 2021
Table 53: Eli Lilly and Co.: Business Segments
Table 54: Eli Lilly and Co.: Marketed Osteoporosis Products
Table 55: Eli Lilly and Co.: Financial Performance, 2018-2021
Table 56: Eli Lilly and Co.: Oncology Pharmaceuticals Product Portfolio
Table 57: Eli Lilly and Co.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 58: Endo International: Key Financials, 2021
Table 59: Gilead Sciences Inc.: Oncology Pharmaceuticals Product Portfolio
Table 60: Gilead Sciences Inc.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 61: Gilead Sciences: Key Financials, 2021
Table 62: GlaxoSmithKline PLC: Product Segment
Table 63: GlaxoSmithKline PLC: Key Financials, 2021
Table 64: GlaxoSmithKline PLC: Vaccines Offered
Table 65: GlaxoSmithKline PLC: Flu Vaccines Sales
Table 66: GlaxoSmithKline PLC: Recent Developments
Table 67: Grifols SA: Product Portfolio
Table 68: Lundbeck: Key Financials, 2021
Table 69: Incyte: Key Financials, 2021
Table 70: Ipsen: Key Financials, 2021
Table 71: Johnson & Johnson: Business Segments
Table 72: Johnson & Johnson: Financials, 2021
Table 73: Johnson & Johnson: Financial Performance, 2018-2021
Table 74: Johnson & Johnson: Product Description
Table 75: Johnson & Johnson: Recent Developments and Strategies
Table 76: Mallinckrodt: Key Financials, 2021
Table 77: Menarini Group: Key Financials, 2021
Table 78: Merck & Co. Inc.: Business Segment
Table 79: Merck & Co. Inc.: Financial Performance, 2018-2021
Table 80: Merck KGaA: Key Financials, 2021
Table 81: Moderna: Key Financials, 2021
Table 82: Novartis: Oncology Pharmaceuticals Product Portfolio
Table 83: Novartis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 84: Novartis: Key Financials, 2021
Table 85: Novartis Key Developments
Table 86: Novo Nordisk: Product Portfolio
Table 87: Novo Nordisk: Key Financials, 2021
Table 88: Otsuka Holdings Co. Ltd.: Key Financials, 2021
Table 89: Otsuka Holdings Co. Ltd.: Key Developments
Table 90: Pfizer: Product Segments
Table 91: Pfizer: Oncology Pharmaceuticals Product Portfolio
Table 92: Pfizer: Oncology Pharmaceuticals Revenue, 2018-2020
Table 93: Pfizer: Women’s Health-Marketed Products by Indication
Table 94: Pfizer: Key Financials, 2021
Table 95: Regeneron: Key Financials, 2021
Table 96: Roche: Business Segment
Table 97: Roche: Financials, 2021
Table 98: Roche: Financial Performance, 2018-2020
Table 99: Roche: Revenues, by Segment, 2016-2018
Table 100: Roche: Revenues, by Diagnostic Segment, 2016-2018
Table 101: Roche: Product Portfolio
Table 102: Roche: Diagnostics Patient Monitoring Product Portfolio
Table 103: Roche: Oncology Pharmaceuticals Product Portfolio
Table 104: Roche: Oncology Pharmaceuticals Revenue, 2018-2020
Table 105: Roche: Key Developments
Table 106: Sanofi: Business Segment
Table 107: Sanofi: Financial Performance, 2021
Table 108: Sanofi: Oncology Pharmaceuticals Product Portfolio
Table 109: Sanofi: Oncology Pharmaceuticals Revenue, 2018-2020
Table 110: Servier: Key Financials, 2021
Table 111: Shionogi: Key Financials, 2021
Table 112: Sinopharm: Key Financials, 2021
Table 113: Stada Arzneimittel: Key Financials, 2021
Table 114: Sumitomo Dainippon Pharma: Key Financials, 2021
Table 115: Sun Pharmaceutical: Key Financials, 2021
Table 116: Takeda: Oncology Pharmaceuticals Product Portfolio
Table 117: Takeda: Oncology Pharmaceuticals Revenue, 2019-2021
Table 118: Takeda: Key Financials, 2021
Table 119: Teva: Key Financials 2021
Table 120: UCB: Key Financials, 2021
Table 121: Vertex: Key Financials, 2021
Table 122: Vertex: Recent Developments
Table 123: Viatris: Top Product Portfolio
Table 124: Viatris: Key Financials, 2021
Table 125: Viatris: Key Developments
Table 1: Top 20 Pharmaceutical Companies, R&D Expenditures, 2021
Table 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Table 3: Countries/Region that Authorized Moderna’s Vaccine for COVID-19
Table 4: Standard Vaccine Pricing Process in the U.S.
Table 5: COVID-19 Vaccine Price Range in the U.S., by Federal Government Purchase
Table 6: Global Pharmaceutical Drug Manufacturers Market Share, 2021
Table 7: Global Pharmaceutical Drug Manufacturers Key Financials 2021
Table 8: Global Pharmaceutical Drug Manufacturers R&D Expenditure and % of R&D in Revenue, by Company, 2021
Table 9: Top 50 Best-Selling Pharmaceuticals, 2021
Table 10: Global Market for Pharmaceutical Drugs, 2016-2020
Table 11: Global Market for Pharmaceutical Drugs, Through 2027
Table 12: Global Market for Pharmaceutical Drugs, by Region, 2016-2020
Table 13: Global Market for Pharmaceutical Drugs, by Region, Through 2027
Table 14: Certification, Reorganization, R&D Facilities and Services and Solutions in the Pharmaceuticals Market
Table 15: Abbott: Financials, 2016-2021
Table 16: Abbott: Product Portfolio, by Business Segment 2021
Table 17: Abbott: Recent Developments, 2015-2020
Table 18: AbbVie: Oncology Pharmaceutical Product Portfolio
Table 19: AbbVie: Oncology Pharmaceutical Revenue, 2018-2020
Table 20: AbbVie Inc.: Marketed Products
Table 21: AbbVie Inc.: Business Segment
Table 22: AbbVie Inc.: Financial Performance, 2018-2021
Table 23: AbbVie Inc.: Key Developments
Table 24: Alexion: Financial Performance, 2020
Table 25: Alexion: Key Developments
Table 26: Amgen: Financial Performance, 2018-2021
Table 27: Amgen: Financials, 2014-2021
Table 28: Amgen: Oncology Pharmaceuticals Product Portfolio
Table 29: Amgen: Oncology Pharmaceuticals Revenue, 2018-2020
Table 30: Amgen: Key Developments
Table 31: Astellas: Key Financials 2021
Table 32: Astellas: Oncology Pharmaceuticals Product Portfolio
Table 33: Astellas: Oncology Pharmaceuticals Revenue, 2018-2020
Table 34: Astellas: Key Developments
Table 35: AstraZeneca: Financial Performance, 2018-2021
Table 36: AstraZeneca: Oncology Pharmaceuticals Product Portfolio
Table 37: AstraZeneca: Oncology Pharmaceuticals Revenue, 2018-2020
Table 38: Aurobindo Pharma: Financial Performance, 2021
Table 39: Bausch Health Companies Inc.: Product Portfolio of Dermatology Devices
Table 40: Bayer AG: Marketed Products
Table 41: Bayer AG: Oncology Pharmaceuticals Product Portfolio
Table 42: Bayer AG: Oncology Pharmaceuticals Revenue, 2018-2020
Table 43: Bayer AG: Key Financials, 2021
Table 44: Biogen: Key Financials, 2021
Table 45: Bristol-Myers Squibb: Financial Performance, 2018-2021
Table 46: Bristol-Myers Squibb: Oncology Pharmaceuticals Product Portfolio
Table 47: Bristol-Myers Squibb: Oncology Pharmaceuticals Revenue, 2018-2020
Table 48: CSL Ltd. (Seqirus): Vaccines Offered
Table 49: CSL Ltd. (Seqirus): Recent Developments
Table 50: Daiichi Sankyo Co. Ltd.: Net Revenue 2021
Table 51: Dr. Reddy’s: Key Financials 2021
Table 52: Eisai: Key Financials, 2021
Table 53: Eli Lilly and Co.: Business Segments
Table 54: Eli Lilly and Co.: Marketed Osteoporosis Products
Table 55: Eli Lilly and Co.: Financial Performance, 2018-2021
Table 56: Eli Lilly and Co.: Oncology Pharmaceuticals Product Portfolio
Table 57: Eli Lilly and Co.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 58: Endo International: Key Financials, 2021
Table 59: Gilead Sciences Inc.: Oncology Pharmaceuticals Product Portfolio
Table 60: Gilead Sciences Inc.: Oncology Pharmaceuticals Revenue, 2018-2020
Table 61: Gilead Sciences: Key Financials, 2021
Table 62: GlaxoSmithKline PLC: Product Segment
Table 63: GlaxoSmithKline PLC: Key Financials, 2021
Table 64: GlaxoSmithKline PLC: Vaccines Offered
Table 65: GlaxoSmithKline PLC: Flu Vaccines Sales
Table 66: GlaxoSmithKline PLC: Recent Developments
Table 67: Grifols SA: Product Portfolio
Table 68: Lundbeck: Key Financials, 2021
Table 69: Incyte: Key Financials, 2021
Table 70: Ipsen: Key Financials, 2021
Table 71: Johnson & Johnson: Business Segments
Table 72: Johnson & Johnson: Financials, 2021
Table 73: Johnson & Johnson: Financial Performance, 2018-2021
Table 74: Johnson & Johnson: Product Description
Table 75: Johnson & Johnson: Recent Developments and Strategies
Table 76: Mallinckrodt: Key Financials, 2021
Table 77: Menarini Group: Key Financials, 2021
Table 78: Merck & Co. Inc.: Business Segment
Table 79: Merck & Co. Inc.: Financial Performance, 2018-2021
Table 80: Merck KGaA: Key Financials, 2021
Table 81: Moderna: Key Financials, 2021
Table 82: Novartis: Oncology Pharmaceuticals Product Portfolio
Table 83: Novartis: Oncology Pharmaceuticals Revenue, 2018-2020
Table 84: Novartis: Key Financials, 2021
Table 85: Novartis Key Developments
Table 86: Novo Nordisk: Product Portfolio
Table 87: Novo Nordisk: Key Financials, 2021
Table 88: Otsuka Holdings Co. Ltd.: Key Financials, 2021
Table 89: Otsuka Holdings Co. Ltd.: Key Developments
Table 90: Pfizer: Product Segments
Table 91: Pfizer: Oncology Pharmaceuticals Product Portfolio
Table 92: Pfizer: Oncology Pharmaceuticals Revenue, 2018-2020
Table 93: Pfizer: Women’s Health-Marketed Products by Indication
Table 94: Pfizer: Key Financials, 2021
Table 95: Regeneron: Key Financials, 2021
Table 96: Roche: Business Segment
Table 97: Roche: Financials, 2021
Table 98: Roche: Financial Performance, 2018-2020
Table 99: Roche: Revenues, by Segment, 2016-2018
Table 100: Roche: Revenues, by Diagnostic Segment, 2016-2018
Table 101: Roche: Product Portfolio
Table 102: Roche: Diagnostics Patient Monitoring Product Portfolio
Table 103: Roche: Oncology Pharmaceuticals Product Portfolio
Table 104: Roche: Oncology Pharmaceuticals Revenue, 2018-2020
Table 105: Roche: Key Developments
Table 106: Sanofi: Business Segment
Table 107: Sanofi: Financial Performance, 2021
Table 108: Sanofi: Oncology Pharmaceuticals Product Portfolio
Table 109: Sanofi: Oncology Pharmaceuticals Revenue, 2018-2020
Table 110: Servier: Key Financials, 2021
Table 111: Shionogi: Key Financials, 2021
Table 112: Sinopharm: Key Financials, 2021
Table 113: Stada Arzneimittel: Key Financials, 2021
Table 114: Sumitomo Dainippon Pharma: Key Financials, 2021
Table 115: Sun Pharmaceutical: Key Financials, 2021
Table 116: Takeda: Oncology Pharmaceuticals Product Portfolio
Table 117: Takeda: Oncology Pharmaceuticals Revenue, 2019-2021
Table 118: Takeda: Key Financials, 2021
Table 119: Teva: Key Financials 2021
Table 120: UCB: Key Financials, 2021
Table 121: Vertex: Key Financials, 2021
Table 122: Vertex: Recent Developments
Table 123: Viatris: Top Product Portfolio
Table 124: Viatris: Key Financials, 2021
Table 125: Viatris: Key Developments
LIST OF FIGURES
Figure 1: Stakeholders Involved in the Innovation Process
Figure 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Figure 3: Global Age 60+ Population, by Region, 2015-2050
Figure 4: Global Projected Growth Rate, Diabetes and Impaired Glucose Tolerance in Patients Aged, 20-79 Years, 2010 and 2030
Figure 5: Global Company Market Shares of Pharmaceutical Drugs, 2021
Figure 6: Abbott: Revenue Share, by Region/Country, 2021
Figure 7: Abbott: Revenue Share, by Business Segment, 2021
Figure 8: Abbott: R&D Expenditure, 2015-2021
Figure 9: AbbVie: Hematologic Oncology Annual Revenue, 2018-2021
Figure 10: AbbVie Inc.: Net Revenue Share, by Business Segment, 2021
Figure 11: AbbVie Inc.: Net Revenue Share, by Region, 2021
Figure 12: AbbVie Inc.: Revenue Share, by Country, 2021
Figure 13: Alexion: Net Revenue Share, by Business Segment, 2020
Figure 14: Alexion: Net Revenue Share, by Region/Country, 2020
Figure 15: Amgen: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 16: Amgen: Sales Share, by Product, 2021
Figure 17: Amgen: Revenue Share, by Region, 2021
Figure 18: Astellas: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 19: AstraZeneca: Sales Share, by Segment, 2021
Figure 20: AstraZeneca: Revenue Share, by Region, 2021
Figure 21: AstraZeneca: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2021
Figure 22: Aurobindo Pharma: Net Revenue Share, by Region/Country, 2021
Figure 23: Bausch Health Companies Inc.: Annual Revenue, 2017-2021
Figure 24: Bausch Health Companies Inc.: Revenue Share, by Segment, 2021
Figure 25: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 26: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 27: Bayer AG: Revenue Share, by Region, 2021
Figure 28: Bayer AG: Revenue Share, by Business Segment, 2021
Figure 29: Biogen: Sales Share, by Product, 2021
Figure 30: Biogen: Revenue Share, by Region/Country, 2021
Figure 31: Boehringer Ingelheim: Annual Revenue, 2021
Figure 32: Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
Figure 33: Boehringer Ingelheim: Revenue Share, by Region, 2021
Figure 34: Bristol Myers Squibb: Sales Share, by Product, 2021
Figure 35: Bristol-Myers Squibb: Total Revenue Share, by Region/Country, 2021
Figure 36: Bristol-Myers Squibb: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 37: CSL Ltd. (Seqirus): Net Revenue, 2017-2021
Figure 38: CSL Ltd.: Revenue Share, by Business Segment, 2021
Figure 39: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 40: Dr. Reddy’s: Revenue Share, by Business Segment, 2021
Figure 41: Eli Lilly and Co.: Total Sales Share, by Product Segment, 2020
Figure 42: Eli Lilly and Co.: Revenue Share, by Product, 2020
Figure 43: Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
Figure 44: Eli Lilly and Co.: Total Revenue Share, by Region, 2020
Figure 45: Endo International: Revenue Share, by Business Segment, 2021
Figure 46: Endo International: Total Revenue Share, by Region, 2021
Figure 47: Gilead Sciences Inc.: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 48: Gilead Sciences: Revenue Share, by Business Segment, 2021
Figure 49: Gilead Sciences: Total Revenue Share, by Region/Country, 2021
Figure 50: GlaxoSmithKline PLC: Net Revenue, 2016-2021
Figure 51: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
Figure 52: GlaxoSmithKline PLC: Revenue Share, by Region/Country, 2021
Figure 53: Grifols SA: Annual Revenue, 2018-2021
Figure 54: Grifols SA: Revenue Share, by Segment, 2021
Figure 55: Grifols SA: Revenue Share, by Region/Country, 2021
Figure 56: Lundbeck: Revenue Share, by Business Segment, 2021
Figure 57: Lundbeck: Total Revenue Share, by Region, 2021
Figure 58: Incyte: Revenue Share, by Business Segment, 2021
Figure 59: Johnson & Johnson: Financials, 2017-2021
Figure 60: Johnson & Johnson: Total Sales Share, by Business Segment, 2021
Figure 61: Johnson & Johnson: Total Revenue Share, by Region/Country, 2021
Figure 62: Mallinckrodt: Revenue Share, by Business Segment, 2021
Figure 63: Mallinckrodt: Total Revenue Share, by Region/Country, 2021
Figure 64: Menarini Group: Revenue Share, by Business Segment, 2021
Figure 65: Menarini Group: Total Revenue Share, by Region/Country, 2021
Figure 66: Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 67: Merck & Co. Inc.: Revenue Share, by Region/Country, 2021
Figure 68: Merck KGaA: Revenue Share, by Business Segment, 2021
Figure 69: Merck KGaA: Total Revenue Share, by Region, 2021
Figure 70: Novartis: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2020
Figure 71: Novartis: Revenue Share, by Business Segment, 2021
Figure 72: Novartis: Total Revenue Share, by Region, 2021
Figure 73: Novo Nordisk: Revenue Share, by Region, 2021
Figure 74: Novo Nordisk: Revenue Share, by Business Segment, 2021
Figure 75: Otsuka Holdings Co. Ltd.: Annual Revenue, 2018-2021
Figure 76: Otsuka Holdings Co. Ltd.: Revenue Share, by Segment, 2020
Figure 77: Pfizer: Oncology Segment Annual Revenue, 2018-2020
Figure 78: Pfizer: Revenue Share, by Region/Country, 2021
Figure 79: Pfizer: Revenue Share, by Business Segment, 2021
Figure 80: Regeneron: Revenue Share, by Business Segment, 2021
Figure 81: Roche: Revenue Share, by Segment, 2021
Figure 82: Roche: Total Sales Share, by Product Segment, 2020
Figure 83: Roche: Oncology Annual Revenue, 2018-2020
Figure 84: Sanofi: Net Sales Share, by Business Segment, 2021
Figure 85: Sanofi: Net Sales Share, by Region/Country, 2021
Figure 86: Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 87: Servier: Revenue Share, by Business Segment, 2021
Figure 88: Servier: Total Revenue Share, by Region, 2021
Figure 89: Stada Arzneimittel: Revenue Share, by Business Segment, 2021
Figure 90: Stada Arzneimittel: Total Revenue Share, by Region/Country, 2021
Figure 91: Sumitomo Dainippon Pharma: Revenue Share, by Business Segment, 2021
Figure 92: Sun Pharmaceutical: Revenue Share, by Business Segment, 2021
Figure 93: Sun Pharmaceutical: Total Revenue Share, by Region/Country, 2021
Figure 94: Takeda: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 95: Takeda: Revenue Share, by Business Segment, 2021
Figure 96: Takeda Pharmaceutical: Total Revenue Share, by Region/Country, 2021
Figure 97: Teva: Annual Revenue, 2018-2020
Figure 98: Teva: Revenue Share, by Business Segment, 2021
Figure 99: Teva: Total Revenue Share, by Region, 2021
Figure 100: UCB: Revenue Share, by Business Segment, 2021
Figure 101: UCB: Total Revenue Share, by Region, 2021
Figure 102: Vertex: Revenue Share, by Business Segment, 2021
Figure 103: Vertex: Total Revenue Share, by Region/Country, 2021
Figure 104: Viatris: Annual Revenue, 2018-2021
Figure 105: Viatris: Revenue Share, by Product Category, 2021
Figure 1: Stakeholders Involved in the Innovation Process
Figure 2: Trends in Per Capita Real Gross Domestic Product Growth, by Region, 2016-2019
Figure 3: Global Age 60+ Population, by Region, 2015-2050
Figure 4: Global Projected Growth Rate, Diabetes and Impaired Glucose Tolerance in Patients Aged, 20-79 Years, 2010 and 2030
Figure 5: Global Company Market Shares of Pharmaceutical Drugs, 2021
Figure 6: Abbott: Revenue Share, by Region/Country, 2021
Figure 7: Abbott: Revenue Share, by Business Segment, 2021
Figure 8: Abbott: R&D Expenditure, 2015-2021
Figure 9: AbbVie: Hematologic Oncology Annual Revenue, 2018-2021
Figure 10: AbbVie Inc.: Net Revenue Share, by Business Segment, 2021
Figure 11: AbbVie Inc.: Net Revenue Share, by Region, 2021
Figure 12: AbbVie Inc.: Revenue Share, by Country, 2021
Figure 13: Alexion: Net Revenue Share, by Business Segment, 2020
Figure 14: Alexion: Net Revenue Share, by Region/Country, 2020
Figure 15: Amgen: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 16: Amgen: Sales Share, by Product, 2021
Figure 17: Amgen: Revenue Share, by Region, 2021
Figure 18: Astellas: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 19: AstraZeneca: Sales Share, by Segment, 2021
Figure 20: AstraZeneca: Revenue Share, by Region, 2021
Figure 21: AstraZeneca: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2021
Figure 22: Aurobindo Pharma: Net Revenue Share, by Region/Country, 2021
Figure 23: Bausch Health Companies Inc.: Annual Revenue, 2017-2021
Figure 24: Bausch Health Companies Inc.: Revenue Share, by Segment, 2021
Figure 25: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 26: Bayer AG: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 27: Bayer AG: Revenue Share, by Region, 2021
Figure 28: Bayer AG: Revenue Share, by Business Segment, 2021
Figure 29: Biogen: Sales Share, by Product, 2021
Figure 30: Biogen: Revenue Share, by Region/Country, 2021
Figure 31: Boehringer Ingelheim: Annual Revenue, 2021
Figure 32: Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
Figure 33: Boehringer Ingelheim: Revenue Share, by Region, 2021
Figure 34: Bristol Myers Squibb: Sales Share, by Product, 2021
Figure 35: Bristol-Myers Squibb: Total Revenue Share, by Region/Country, 2021
Figure 36: Bristol-Myers Squibb: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 37: CSL Ltd. (Seqirus): Net Revenue, 2017-2021
Figure 38: CSL Ltd.: Revenue Share, by Business Segment, 2021
Figure 39: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 40: Dr. Reddy’s: Revenue Share, by Business Segment, 2021
Figure 41: Eli Lilly and Co.: Total Sales Share, by Product Segment, 2020
Figure 42: Eli Lilly and Co.: Revenue Share, by Product, 2020
Figure 43: Eli Lilly and Co.: Oncology Annual Revenue, 2018-2020
Figure 44: Eli Lilly and Co.: Total Revenue Share, by Region, 2020
Figure 45: Endo International: Revenue Share, by Business Segment, 2021
Figure 46: Endo International: Total Revenue Share, by Region, 2021
Figure 47: Gilead Sciences Inc.: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 48: Gilead Sciences: Revenue Share, by Business Segment, 2021
Figure 49: Gilead Sciences: Total Revenue Share, by Region/Country, 2021
Figure 50: GlaxoSmithKline PLC: Net Revenue, 2016-2021
Figure 51: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
Figure 52: GlaxoSmithKline PLC: Revenue Share, by Region/Country, 2021
Figure 53: Grifols SA: Annual Revenue, 2018-2021
Figure 54: Grifols SA: Revenue Share, by Segment, 2021
Figure 55: Grifols SA: Revenue Share, by Region/Country, 2021
Figure 56: Lundbeck: Revenue Share, by Business Segment, 2021
Figure 57: Lundbeck: Total Revenue Share, by Region, 2021
Figure 58: Incyte: Revenue Share, by Business Segment, 2021
Figure 59: Johnson & Johnson: Financials, 2017-2021
Figure 60: Johnson & Johnson: Total Sales Share, by Business Segment, 2021
Figure 61: Johnson & Johnson: Total Revenue Share, by Region/Country, 2021
Figure 62: Mallinckrodt: Revenue Share, by Business Segment, 2021
Figure 63: Mallinckrodt: Total Revenue Share, by Region/Country, 2021
Figure 64: Menarini Group: Revenue Share, by Business Segment, 2021
Figure 65: Menarini Group: Total Revenue Share, by Region/Country, 2021
Figure 66: Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 67: Merck & Co. Inc.: Revenue Share, by Region/Country, 2021
Figure 68: Merck KGaA: Revenue Share, by Business Segment, 2021
Figure 69: Merck KGaA: Total Revenue Share, by Region, 2021
Figure 70: Novartis: Oncology Pharmaceuticals Segment Annual Revenue, 2018-2020
Figure 71: Novartis: Revenue Share, by Business Segment, 2021
Figure 72: Novartis: Total Revenue Share, by Region, 2021
Figure 73: Novo Nordisk: Revenue Share, by Region, 2021
Figure 74: Novo Nordisk: Revenue Share, by Business Segment, 2021
Figure 75: Otsuka Holdings Co. Ltd.: Annual Revenue, 2018-2021
Figure 76: Otsuka Holdings Co. Ltd.: Revenue Share, by Segment, 2020
Figure 77: Pfizer: Oncology Segment Annual Revenue, 2018-2020
Figure 78: Pfizer: Revenue Share, by Region/Country, 2021
Figure 79: Pfizer: Revenue Share, by Business Segment, 2021
Figure 80: Regeneron: Revenue Share, by Business Segment, 2021
Figure 81: Roche: Revenue Share, by Segment, 2021
Figure 82: Roche: Total Sales Share, by Product Segment, 2020
Figure 83: Roche: Oncology Annual Revenue, 2018-2020
Figure 84: Sanofi: Net Sales Share, by Business Segment, 2021
Figure 85: Sanofi: Net Sales Share, by Region/Country, 2021
Figure 86: Sanofi: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 87: Servier: Revenue Share, by Business Segment, 2021
Figure 88: Servier: Total Revenue Share, by Region, 2021
Figure 89: Stada Arzneimittel: Revenue Share, by Business Segment, 2021
Figure 90: Stada Arzneimittel: Total Revenue Share, by Region/Country, 2021
Figure 91: Sumitomo Dainippon Pharma: Revenue Share, by Business Segment, 2021
Figure 92: Sun Pharmaceutical: Revenue Share, by Business Segment, 2021
Figure 93: Sun Pharmaceutical: Total Revenue Share, by Region/Country, 2021
Figure 94: Takeda: Oncology Pharmaceuticals Annual Revenue, 2018-2020
Figure 95: Takeda: Revenue Share, by Business Segment, 2021
Figure 96: Takeda Pharmaceutical: Total Revenue Share, by Region/Country, 2021
Figure 97: Teva: Annual Revenue, 2018-2020
Figure 98: Teva: Revenue Share, by Business Segment, 2021
Figure 99: Teva: Total Revenue Share, by Region, 2021
Figure 100: UCB: Revenue Share, by Business Segment, 2021
Figure 101: UCB: Total Revenue Share, by Region, 2021
Figure 102: Vertex: Revenue Share, by Business Segment, 2021
Figure 103: Vertex: Total Revenue Share, by Region/Country, 2021
Figure 104: Viatris: Annual Revenue, 2018-2021
Figure 105: Viatris: Revenue Share, by Product Category, 2021
